Haemaccel

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Haemaccel (a registered trademark) is a type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma (burns, peritonitis, pancreatitis, crush injuries), or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin.

It is used as an alternative to human albumin solution (HAS) and starch in supportive treatment of ascites following the procedure of paracentesis. Polygelin is excreted via the kidneys and has a plasma half-life of three to six hours. This is increased to up to 16 hours in patients with kidney damage.

Adverse drug reactions were observed in 0.78% of cases mainly due to histamine release (drop in blood pressure, bronchospasm and skin involvement such as urticaria). Haemaccel (also marketed as Emagel in Italy, Polygeline in China and Solucel in Venezuela) was originally brought to market by Hoechst AG and later acquired by Piramal Enterprises.

Haemaccel (a registered trademark) is a type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma (burns, peritonitis, pancreatitis, crush injuries), or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin.

It is used as an alternative to human albumin solution (HAS) and starch in supportive treatment of ascites following the procedure of paracentesis. Polygelin is excreted via the kidneys and has a plasma half-life of three to six hours. This is increased to up to 16 hours in patients with kidney damage.

Adverse drug reactions were observed in 0.78% of cases mainly due to histamine release (drop in blood pressure, bronchospasm and skin involvement such as urticaria). Haemaccel (also marketed as Emagel in Italy, Polygeline in China and Solucel in Venezuela) was originally brought to market by Hoechst AG and later acquired by Piramal Enterprises.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1308207475 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.